Xponance Inc. Acquires 232 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Xponance Inc. grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,891 shares of the company’s stock after purchasing an additional 232 shares during the quarter. Xponance Inc.’s holdings in Axsome Therapeutics were worth $337,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of AXSM. Assenagon Asset Management S.A. raised its stake in shares of Axsome Therapeutics by 16,852.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company’s stock worth $73,176,000 after acquiring an additional 623,717 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $39,767,000. Lazard Asset Management LLC raised its stake in shares of Axsome Therapeutics by 525.7% during the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company’s stock worth $45,492,000 after acquiring an additional 451,737 shares in the last quarter. Norges Bank bought a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $34,100,000. Finally, BVF Inc. IL raised its stake in shares of Axsome Therapeutics by 32.7% during the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after acquiring an additional 342,064 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.5%

Shares of AXSM stock opened at $111.70 on Friday. The company has a market capitalization of $5.50 billion, a price-to-earnings ratio of -19.36 and a beta of 0.46. Axsome Therapeutics, Inc. has a twelve month low of $72.21 and a twelve month high of $139.13. The company has a current ratio of 2.03, a quick ratio of 1.96 and a debt-to-equity ratio of 3.48. The firm has a 50-day moving average price of $106.55 and a 200 day moving average price of $109.14.

Insider Buying and Selling

In related news, General Counsel Hunter R. Murdock sold 6,014 shares of the stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark Coleman sold 3,750 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the sale, the director directly owned 50,387 shares of the company’s stock, valued at approximately $5,314,316.89. This trade represents a 6.93% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,437 shares of company stock valued at $9,834,215. 22.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AXSM shares. Jefferies Financial Group started coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They set a “buy” rating and a $200.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Morgan Stanley began coverage on shares of Axsome Therapeutics in a report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 price target on the stock. Wells Fargo & Company restated an “overweight” rating and set a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. Finally, Mizuho upped their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $172.33.

Get Our Latest Stock Report on Axsome Therapeutics

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Featured Articles

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.